Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $11.6667.

Several equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Acrivon Therapeutics in a research report on Tuesday, November 25th. Piper Sandler increased their price objective on Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Wall Street Zen lowered Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday.

Acrivon Therapeutics Price Performance

ACRV opened at $1.75 on Monday. The stock’s 50 day moving average price is $2.33 and its 200 day moving average price is $1.80. The stock has a market cap of $55.23 million, a P/E ratio of -0.82 and a beta of 1.73. Acrivon Therapeutics has a 12 month low of $1.05 and a 12 month high of $8.00.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.10. Equities analysts anticipate that Acrivon Therapeutics will post -2.49 EPS for the current year.

Institutional Trading of Acrivon Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Quadrature Capital Ltd acquired a new position in shares of Acrivon Therapeutics in the second quarter worth about $26,000. Nuveen LLC purchased a new stake in shares of Acrivon Therapeutics in the 1st quarter valued at approximately $27,000. Focus Partners Wealth acquired a new position in Acrivon Therapeutics in the 3rd quarter worth approximately $36,000. Invesco Ltd. purchased a new position in Acrivon Therapeutics during the 1st quarter worth approximately $72,000. Finally, Algert Global LLC purchased a new position in Acrivon Therapeutics during the 3rd quarter worth approximately $81,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.